136 related articles for article (PubMed ID: 446410)
1. On the role of the central serotoninergic system in the regulation of the secretion of thyrotropin and prolactin: thyrotropin-inhibiting and prolactin-releasing effects of 5-hydroxytryptamine and quipazine in the male rat.
Krulich L; Vijayan E; Coppings RJ; Giachetti A; McCann SM; Mayfield MA
Endocrinology; 1979 Jul; 105(1):276-83. PubMed ID: 446410
[No Abstract] [Full Text] [Related]
2. On the mode of the prolactin release-inhibiting action of the serotonin receptor blockers metergoline, methysergide, and cyproheptadine.
Krulich L; McCann SM; Mayfield MA
Endocrinology; 1981 Apr; 108(4):1115-24. PubMed ID: 7472261
[TBL] [Abstract][Full Text] [Related]
3. Lack of evidence that the central serotoninergic system plays a role in the activation of prolactin secretion following inhibition of dopamine synthesis or blockade of dopamine receptors in the male rat.
Krulich L; Coppings RJ; Giachetti A; McCann SM; Mayfield MA
Neuroendocrinology; 1980; 30(3):133-8. PubMed ID: 6445044
[TBL] [Abstract][Full Text] [Related]
4. Involvement of brain serotonin in the prolactin-releasing effect of opioid peptides.
Spampinato S; Locatelli V; Cocchi D; Vicentini L; Bajusz S; Ferri S; Müller EE
Endocrinology; 1979 Jul; 105(1):163-70. PubMed ID: 221198
[No Abstract] [Full Text] [Related]
5. Effects of quipazine on blood pressure in pithed rats.
Shin YK; Svinareff P; Schmitt-Jubeau H; Schmitt H
Arch Int Pharmacodyn Ther; 1983 Jul; 264(1):73-81. PubMed ID: 6138006
[TBL] [Abstract][Full Text] [Related]
6. The influence of pharmacological manipulation of serotonergic and dopaminergic mechanisms on plasma prolactin in ovariectomized, estrogen-treated rats.
Lawson DM; Gala RR
Endocrinology; 1978 Mar; 102(3):973-81. PubMed ID: 311279
[No Abstract] [Full Text] [Related]
7. Comparison of the behavioral effects of para-chloroamphetamine, chlordimeform, quipazine, and intraventricular serotonin in the rat.
Pfister WR; Noland V; Lowy MT; Nichols DE; Yim GK
Commun Psychopharmacol; 1978; 2(4):287-95. PubMed ID: 729354
[No Abstract] [Full Text] [Related]
8. 5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine.
Rokosz-Pelc A; Antkiewicz-Michaluk L; Vetulani J
J Pharm Pharmacol; 1980 Mar; 32(3):220-2. PubMed ID: 6103943
[No Abstract] [Full Text] [Related]
9. Further evidence that prolactin secretion in adult female rats is differently modified after neonatal estrogenization or androgenization: responses to methysergide, quipazine, and pizotifen.
Collado D; Aguilar E
Physiol Behav; 1993 Jan; 53(1):161-5. PubMed ID: 8434056
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of prolactin secretion by a direct effect of methysergide on the pituitary lactotrophs in the rat.
Krulich L; Coppings RJ; McCann SM; Mayfield MA
Life Sci; 1978 Oct; 23(16):1665-73. PubMed ID: 723442
[No Abstract] [Full Text] [Related]
11. Serotonin neuroleptics change patterns of preovulatory secretion of luteinizing hormone in rats.
Walker RF
Life Sci; 1980 Sep; 27(12):1063-8. PubMed ID: 7191463
[No Abstract] [Full Text] [Related]
12. Effect of clonidine, quipazine, and LY 53857 on the prolactin-suppressant action of bromocriptine in rats.
Lipham LB; Booth NH; Jernigan AD; Robbins JD; Hatch RC
Am J Vet Res; 1986 May; 47(5):1089-91. PubMed ID: 3717731
[TBL] [Abstract][Full Text] [Related]
13. Effects of parachlorophenylalanine, quipazine and cyproheptadine on growth hormone and adrenocorticotropin secretion in steers.
Sartin JL; Kemppainen RJ; Marple DN; Carnes R; Dieberg G; Oliver EH
Domest Anim Endocrinol; 1987 Jan; 4(1):33-41. PubMed ID: 2853663
[TBL] [Abstract][Full Text] [Related]
14. Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion.
Bero LA; Kuhn CM
J Pharmacol Exp Ther; 1987 Mar; 240(3):825-30. PubMed ID: 3031276
[TBL] [Abstract][Full Text] [Related]
15. Opiate-serotonin synergism stimulating luteinizing hormone release in estrogen-progesterone-primed ovariectomized rats: mediation by serotonin2 receptors.
Lenahan SE; Seibel HR; Johnson JH
Endocrinology; 1987 Apr; 120(4):1498-502. PubMed ID: 3830057
[TBL] [Abstract][Full Text] [Related]
16. Effects of the serotonin agonist, quipazine, on luteinizing hormone and prolactin release: evidence for serotonin-catecholamine interactions.
Lynch CO; Johnson MD; Crowley WR
Life Sci; 1984 Oct; 35(14):1481-7. PubMed ID: 6148678
[TBL] [Abstract][Full Text] [Related]
17. The combined effect of quipazine and haloperidol on plasma prolactin release.
Feigenbaum J; Yanai J; Klawans HL; Chatterton R
Int J Neurosci; 1983; 18(1-2):37-40. PubMed ID: 6840980
[TBL] [Abstract][Full Text] [Related]
18. Effects of quipazine and methysergide on play in juvenile rats.
Normansell L; Panksepp J
Pharmacol Biochem Behav; 1985 May; 22(5):885-7. PubMed ID: 2989950
[TBL] [Abstract][Full Text] [Related]
19. On the central anti-serotoninergic actions of cyproheptadine and methysergide.
Jacoby JH; Poulakos JJ; Bryce GF
Neuropharmacology; 1978; 17(4-5):299-306. PubMed ID: 652142
[No Abstract] [Full Text] [Related]
20. Complex role of 5-HT in the regulation of TSH secretion in the male rat.
Mattila J; Männistö PT
Horm Res; 1981; 14(3):165-71. PubMed ID: 6456976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
